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teaching process occurrences of non-compliance, lnisnnder- 
standing and miscommunication can still occur. We will also 
show different ways staff evaluates medication administration 
and compliance. 
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Allogeneic stem cell transplantation has been the cornerstone in 
long-term survival for many hematologic malignancies. Unfortu- 
nately, the myeloablative chemotherapy regimens can often be too 
rigorous for some patients. Non-myeloablative allogeneic stem 
cell transplantation is a relatively new concept in cancer treatment 
that can offer a potential benefit with less toxicity to patients who 
would not otherwise qualify for myeloablative treatment. The 
non-myeloablative preparative regimen is less toxic to the patient 
who can then benefit from the graft versus malignancy effect that 
the allogeneic stem cells can provide. Donor lymphocyte infilsions 
(DLI) are often given after t ansplantation to boost donor engraft- 
ment or to treat residual disease but can be associated with an 
increased risk of graft versus host disease. *When dosed correctly 
and at the appropriate time following the transplant, DLIs can be 
crucial in achieving 100% donor engraftment with minimal risk. 
This poster will review DLI dosages and associated toxicities in 37 
adult patients in a clinical trial using a non-myeloablative prepara- 
tive regimen followed by allogeneic transplant and post transplant 
DLIs. Developing a standard for dosing and transfusing DLls 
with minimal risk provides a unique challenge to our entire health 
care team and is an area that needs further esearch. 
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Blood and Marrow Transplantation (BMT) patients are very 
susceptible to infections particularly of a fungal source. Invasive 
fimgal infections carry a high morbidity and mortality rate. Clini- 
cians are now taking a new approach to treat fungal infections due 
to recurrence, occurrence of resistant infections, aud increasing 
risk factors of transnfission of infection in susceptible hosts espe 
cially those patients with hematological disease or ou innnunosup- 
presive therapy. Most common fungal pathogens are of the Candi 
da species and Aspergillns pecies. Antifungal treamaent is given 
prior to and post BMT. Traditional treatment of choice to pre- 
vent fungal infection in BMT recipients is Fluconazole or Itra- 
conazole. In the treatment of fungal infection, the chosen thera- 
peutic option is Aurphotericin B or its lipid formation. The 
response to the current antifungal medications varies in patients. 
Monitoring of adverse reactions uch as chills, fever, and anaphy- 
laxis is also a priority; therefore premedications are necessary prior 
to the administration of Amphotericin B. Due to the effects these 
agents have on kidney and liver function, dosing of the medica- 
tions is critical. Despite the current treatments, resistant infections 
are beconaing a serious problem. In r~sponse to the problem of 
resistant fimgal infections: combination therapy or newer agents 
like Voriconazole and Caspofungin arc being used. Voriconazole 
and Caspofungin are less toxic on the kidneys and liver, premed- 
ications are not required, and thus better tolerated by BMT 
patients. A case study will be presented including prophylactic 
naanagelnent aswell as treatment of a BMT patient with fnngal 
infection. Continued research is being done to determine the best 
uses of these agents ahme or in combination therapy in order to 
better treat fungal infections in our BMT patients and decrease 
toxicities. 
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THE COMPLEXITY OF TRANSITIONING BLOOD AND MARROW 
PATIENTS FROM OUTPATIENT TO INPATIENT 
Cala'mm'a, J.M.; Stray, S.; Nemnam~, J.; Adorlletto, D.; Jolmstom P. 
~ID AmlersoTz Cm2cer Ce~zte~; Houstol~, TX. 
Transitioning the blood and marrow transplant patient from the 
outpatient clinic to the inpatient setting in a large comprehensive 
cancer center, perforuaing over 550 transplants a year, can be a 
challenging and complex process. During a collaborative review of 
this process, it was decided to focus on the admission procedure 
bem~een these areas to assure seamless commnnieation. The goal 
of this process was to provide a more consistent method of com- 
nrunicating information regarding the admission of a patient. The 
transplant team members identified the solution to be the creation 
of a designated admission folder. This fBlder is started for each 
patient being admitted, along with a checldist of required con- 
tents. The checldist is a document in which the outpatient staff 
verifies that the required contents are present in the folder. The 
checklist includes pre-transplant worknp, chemotherapy orders, 
height and weight, psychosocial ssessment by the social workers, 
copy of patient's blood and informed consent, patient's treatment 
plan and flowsheet including a complete disease history. The 
checklist is the key communication tool for staff and must be com- 
pleted before the patient leaves the clinic to be admitted. The 
checklist is completed on the day of admission, and contents of 
the folder reviewed by the transplant physician. The pharmacist 
also uses the iuformation in the folder to assist with writing the 
chemotherapy orders. The clinic nurse completes the checldist 
adding any comments or updates. The folder and checklist is then 
sent to the inpatient unit along with the patient naedicaI record. 
The beuefit o the inpatient unit is that all revelant docmnents are 
organized and placed in a designated folder, thereby, expiditing 
order transcription and the general admission process. At the 
present time, the folder acts as a transition for the electronic med 
ical records system, currently in the developmental stage. This 
folder and checklist creates a standard practice regarding the 
admission process in the Blood and Marrow Transplant clinic for 
the mulitdisiplinary team. A tool is being developed to audit the 
effectiveness of this new process. 
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Transitioning patients through the Blood and Marrow Trans- 
plant (BMT) process requires seamless comnmnication amongst 
various healthcare team members and clinical areas. The treat- 
ment plan is a documentation tool that details the treatment pro- 
tocol and cell infusion for the transplant and serves as the commu- 
nication link between team uaembers in the inpatient and 
outpatient clinical areas. Initially, the treatment plan was imple- 
mented as a tool to communicate the patients transplant therapy 
to thc insurance company and the BMT clinical pharmacist. How- 
ever, it has evolved into the main treatment connnunication tool 
amongst the multidisciplinary teams. Through its evolution the 
need became apparent to standardize the form, establish accounta- 
bility for the team melnbers, and develop a policy and procedure. 
A nmltidisciplinary task tbrce was formed to discuss the current 
process, the purpose of the form, and the concerns related to 
patient safety in the administration of the correct therapy. This 
task force, evaluated the process flow, established policy and pro- 
cedure, standardized the form, and reverified the content of cur- 
rent treatment plans being utilized. Further development of this 
prqcess will include the accessibility of the treatment plans in a 
central repository of the BMT database. This repository will allow 
read and print capabilities to any team member and the ability of 
designated team members to monitor and maintain the repository. 
As a result of this process, treatment plans are utilized as the com- 
munication link to ensure the patients plan of care is clear, accu 
rate, documented, and approved by the attending physician. Also, 
this tool provides conmmnication to all caregivers in the inpatient 
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